Top Page
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
(Sydney:EBR)
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (EBR) vs. iShares MSCI Australia ETF (EWA)
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Business Overview & Revenue Model
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.67M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 507.09K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -47.28M | -37.73M | -24.66M | -23.62M | ― |
| Net Income | -50.46M | -20.17M | -35.04M | -33.09M | ― |
Balance Sheet | |||||
| Total Assets | 97.29M | 73.56M | 78.90M | 71.68M | 85.42M |
| Cash, Cash Equivalents and Short-Term Investments | 53.22M | 60.66M | 72.32M | 63.53M | 78.24M |
| Total Debt | 58.63M | 41.40M | 41.59M | 21.59M | 4.81M |
| Total Liabilities | 71.69M | 49.20M | 47.84M | 27.73M | 9.53M |
| Stockholders Equity | 25.61M | 24.36M | 31.06M | 43.95M | 75.90M |
Cash Flow | |||||
| Free Cash Flow | -58.86M | -41.50M | -33.05M | -31.09M | -934.16K |
| Operating Cash Flow | -55.05M | -41.23M | -32.70M | -30.36M | -22.15K |
| Investing Cash Flow | 8.11M | 1.11M | -8.64M | -49.35M | -906.81K |
| Financing Cash Flow | 48.46M | 32.48M | 40.47M | 17.01M | 95.76M |
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Technical Analysis
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$23.48M | -1.40 | -98.14% | ― | 14.84% | 39.64% | |
45 Neutral | AU$28.36M | -4.09 | -58.40% | ― | -7.20% | 28.70% | |
44 Neutral | AU$301.67M | -4.94 | -152.49% | ― | ― | ― | |
44 Neutral | AU$144.52M | -10.00 | -70.29% | ― | ― | -257.32% | |
41 Neutral | AU$10.75M | -0.50 | 459.94% | ― | -2.82% | 32.47% | |
41 Neutral | AU$44.29M | -2.66 | -180.06% | ― | -14.25% | -22.83% |
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Corporate Events
EBR Systems, Inc., developer of the WiSE wireless cardiac pacing system for heart failure patients, reported its quarterly cash flow for the period ended 31 December 2025, showing continued investment in research and development as it began enrolment in a post-approval study and increased spending on product development. The company also lifted advertising and marketing costs to support commercialization, while administration and corporate expenses rose largely due to prepayment of annual directors’ and officers’ insurance premiums, moves that indicate a ramp-up in commercial activity despite ongoing operating cash outflows.
The cash flow report shows higher operating outlays offset by positive net cash from investing and earlier equity financing, leaving EBR Systems with US$8.4 million in cash and cash equivalents at period end. This financial positioning suggests the company is consciously deploying capital to advance clinical evidence and market penetration for its WiSE technology, with implications for its growth trajectory and the risk-reward balance faced by investors as commercialization progresses.
The most recent analyst rating on (AU:EBR) stock is a Hold with a A$0.79 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.
EBR Systems has notified the ASX of the cessation of 293,697 options, with various expiry dates and exercise prices, after the conditional rights attached to these securities lapsed because the required conditions were not or could not be satisfied. The change reflects an adjustment to the company’s issued capital structure, slightly reducing potential future dilution for existing shareholders without affecting its currently listed ordinary securities.
The lapse of these options is a routine capital management event that may marginally simplify EBR Systems’ equity profile and clarify its outstanding contingent obligations tied to employee or incentive securities. While it does not indicate an immediate operational shift, the notification provides investors with updated transparency on the company’s capital base and the status of conditional equity instruments.
The most recent analyst rating on (AU:EBR) stock is a Hold with a A$0.79 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.
EBR Systems, developer of the WiSE wireless cardiac pacing system, has filed a preliminary proxy statement with U.S. and Australian regulators ahead of its virtual Annual Meeting of Stockholders, scheduled for 7 May 2026 AEST. The meeting will address key governance and incentive matters, including the re-election of two Class II directors, an increase in shares reserved under the 2021 Equity Incentive Plan, and new option grants for the chief executive and directors.
The notice of meeting, which remains subject to regulatory review and potential changes before final dispatch around 27 March 2026, will be made available to both common stock and CHESS Depositary Interest holders via the ASX platform and the company’s website. It will set out how investors can access the virtual meeting, vote online, and submit questions in real time, underscoring EBR Systems’ ongoing engagement with its shareholder base as it advances its specialised cardiac pacing technology.
The most recent analyst rating on (AU:EBR) stock is a Hold with a A$0.79 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.
EBR Systems has appointed Philip Oettinger as its U.S. Corporate Secretary, succeeding John Sellers, who has served in the role since the company’s ASX listing. The board acknowledged Sellers’ contributions while signalling a governance refresh that aligns with the company’s ongoing public-market obligations.
Oettinger, a partner in the life sciences practice at Wilson Sonsini Goodrich & Rosati, brings extensive experience advising medical device, biotech, pharma and digital health companies on corporate governance, capital markets and M&A. His appointment is likely to strengthen EBR Systems’ regulatory and transactional capabilities as it advances commercialization of its WiSE wireless cardiac pacing technology and navigates U.S. securities and reporting requirements.
The most recent analyst rating on (AU:EBR) stock is a Hold with a A$0.79 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.
EBR Systems, Inc. has notified the market of the issue of 1,365,500 unquoted options under its employee incentive scheme, with various expiry dates and exercise prices. The options, which will not be quoted on the ASX, were issued on 2 March 2026 and underscore the company’s ongoing use of equity incentives to align employee interests with long-term shareholder value.
The most recent analyst rating on (AU:EBR) stock is a Hold with a A$0.79 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.
EBR Systems, Inc. has reported a change in the interests of director Allan Will, following the exercise of 58,500 options at US$0.16 per share, resulting in the conversion of these options into an equivalent number of CHESS Depositary Interests. After the transaction, Will’s direct holdings increased to 5,995,724 CDIs, while his remaining options decreased accordingly, and indirect holdings through his partner, Taphne Lux, remained at 600,000 CDIs.
The change reflects a shift from derivative-based exposure to fully paid equity, modestly increasing the director’s direct stake in the company and aligning his interests more closely with ordinary shareholders. Such movements in director holdings are closely monitored by investors as indicators of confidence in the company’s prospects and capital position, although the overall scale of this specific transaction is relatively limited within the broader ownership structure.
The most recent analyst rating on (AU:EBR) stock is a Hold with a A$0.79 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.
EBR Systems reported that all resolutions put to stockholders at its 2026 Special Meeting were decided and passed by poll, complying with relevant ASX listing requirements. The outcome reinforces the company’s corporate governance processes and provides a mandate for the board and management to proceed with their strategic and operational plans.
The company continues to position its WiSE wireless endocardial pacing system as a differentiated solution in the cardiac rhythm management market. As WiSE remains investigational in most markets and currently only available for sale in the U.S., the company’s progress in governance and regulatory alignment will be closely watched by investors and clinical stakeholders.
The most recent analyst rating on (AU:EBR) stock is a Sell with a A$0.76 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.
EBR Systems has released an investor presentation that outlines general information about its activities and financial reporting, emphasizing that the material is a high‑level summary and should not be relied on as standalone investment advice. The document highlights that its CHESS Depositary Interests trade on the ASX under Regulation S, stresses the use of U.S. GAAP and certain non‑IFRS financial data, and underscores legal disclaimers around accuracy, liability, and distribution restrictions for investors in different jurisdictions.
The most recent analyst rating on (AU:EBR) stock is a Hold with a A$0.79 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.
EBR Systems will showcase its wireless cardiac pacing technology to investors at three healthcare and biotech conferences in March in Miami, Sorrento and Hong Kong, with senior executives hosting meetings, presentations and a fireside chat. The company also reported ongoing commercial momentum in early 2026, with quarterly-to-date case volumes rising to 25 procedures, seven new purchasing agreements lifting the total to 28, and the number of trained implanting physicians reaching 46, underscoring growing clinical adoption of its WiSE System.
These increased case volumes and expanded hospital purchasing base suggest the company is progressing from early commercialisation toward broader market penetration in cardiac resynchronisation therapy. For stakeholders, the combination of stronger operating metrics and heightened investor outreach points to an effort to solidify EBR’s positioning in the competitive cardiac device market and support continued uptake of its differentiated leadless pacing technology.
The most recent analyst rating on (AU:EBR) stock is a Hold with a A$0.79 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.
EBR Systems has called a 2026 Special Meeting of Stockholders to be held virtually on 12 March 2026 (AEDT), and has dispatched the Notice of Special Meeting and Proxy Statement, along with voting instruction forms for CHESS Depositary Interest holders and proxy cards for common stockholders. By facilitating electronic participation and voting for its globally dispersed investor base, the company is reinforcing stockholder engagement and governance processes as it advances development and potential commercialization of its wireless cardiac pacing technology.
The most recent analyst rating on (AU:EBR) stock is a Hold with a A$0.92 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.
EBR Systems has called a virtual special meeting of stockholders for 12 March 2026, with the notice of meeting to be made available online around 28 January 2026, to consider changes affecting its capital structure. The company is proposing a consolidation of its common shares within a range of 5-for-1 to 20-for-1, while leaving ASX-listed CDIs unconsolidated and adjusting the CDI-to-common-share conversion ratio proportionately so that both the total number and trading price of EBR’s ASX CDIs remain unchanged, aiming to preserve relative value for CDI holders while potentially improving the profile and structure of its common equity.
The most recent analyst rating on (AU:EBR) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.
EBR Systems will convene a virtual special meeting of stockholders in March 2026 to vote on key corporate actions, including a proposed amendment to its charter to implement a reverse stock split within a 1-for-5 to 1-for-20 range, and the ratification and approval of a prior institutional placement completed in May 2025. The company emphasised that the consolidation will not change its total authorised share capital, the number of issued CHESS Depositary Interests, or the CDI price, with the main mechanical impact being a change in the CDI-to-share transmutation ratio. Communication to securityholders about the meeting will be dispatched in late January, and management will host an investor webinar ahead of the vote to explain the strategic rationale for the share consolidation, underlining EBR Systems’ effort to manage its capital structure while maintaining access to both U.S. and Australian markets.
The most recent analyst rating on (AU:EBR) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.
EBR Systems will present at the 44th Annual J.P. Morgan Healthcare Conference, where President and CEO John McCutcheon is set to brief investors on the company’s commercial progress, clinical programs and strategic priorities aimed at expanding adoption of its WiSE wireless cardiac pacing system. The company also disclosed that its estimated total addressable market has risen from US$3.6 billion to US$5.8 billion, reflecting the rapid expansion of the leadless pacemaker segment and higher expected average selling prices for the WiSE System, underscoring a significantly larger commercial opportunity for the business and its shareholders.
The most recent analyst rating on (AU:EBR) stock is a Hold with a A$0.87 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.
EBR Systems reported strong commercial and clinical progress in the fourth quarter of FY2025, with WiSE System case volumes doubling from the prior quarter to 18 commercial implants and total commercial and pilot implants reaching 30. The company expects to post a sharp step-up in quarterly revenue to between US$870,000 and US$935,000, driven by growing adoption under its Limited Market Release, which now includes 9 additional purchase agreements and a total of 33 trained implanting physicians, while expanding hospital readiness and reimbursement processes for the WiSE technology.
Clinically, EBR advanced two key studies that underpin its long-term growth strategy: the WiSE-UP post-approval study began enrolling patients to generate real-world performance and outcomes data across more than 300 heart failure patients over five years, and the TLC-AU feasibility study enrolled its first patient to evaluate totally leadless CRT in both upgrade and de novo candidates, potentially opening up roughly three-quarters of the CRT market to WiSE as a first-line option. The company also intensified its investor outreach through multiple healthcare and small/mid-cap conferences and roadshows, reinforcing its profile with the investment community as it builds the evidence base and commercial infrastructure needed for broader market adoption of its wireless pacing platform.
The most recent analyst rating on (AU:EBR) stock is a Hold with a A$0.87 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.